CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Circular RNA-mediated tumor immune escape: Mechanistic architecture and nanomedicine-enabled therapeutic reprogramming.
Circular RNA-mediated tumor immune escape: Mechanistic architecture and nanomedicine-enabled therapeutic reprogramming.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
环状RNA(circRNA)已成为肿瘤免疫逃逸的重要调节因子,其作用机制多层次,包括隔离miRNA、作为RNA结合蛋白支架、依赖m⁶A稳定化、重编程代谢和通过外泌体通讯。这些过程共同维持PD-L1表达及稳定性,驱动CD8 T细胞耗竭,促进Treg和MDSC扩增,使巨噬细胞偏向免疫抑制型M2表型,并重塑糖酵解和脂质代谢通路,形成免疫耐受微环境。
同时,外泌体circRNA可传播远距离免疫抑制信号,强化治疗耐药和全身免疫功能障碍。相反,近期发现的一类“免疫激活型circRNA”可诱导铁死亡、免疫原性细胞死亡和STING介导的先天免疫活化,凸显circRNA免疫调节的双重特征。近期纳米医学进展,包括脂质纳米颗粒、聚合物平台和仿生膜包裹载体,已可精准沉默致癌circRNA并高效递送合成治疗性circRNA;这些策略与免疫检查点抑制剂、NK细胞疗法、STING激动剂及铁死亡诱导剂联用显示强效协同作用。尽管递送特异性、生物安全性、生物标志物标准化和脱靶效应等挑战仍存,circRNA生物学与先进纳米技术的结合为开发新一代RNA引导精准癌症免疫治疗带来变革性机遇。
综上,circRNA既是免疫逃逸的关键机制驱动因素,也是纳米医学精准免疫治疗的有前景靶点。
Circular RNAs (circRNAs) have emerged as pivotal regulators of tumor immune escape, acting through multilayered mechanisms that include miRNA sequestration, RNA-binding protein scaffolding, m A-dependent stabilization, metabolic rewiring, and exosomal communication. These processes collectively sustain PD-L1 expression and stability, drive CD8 T-cell exhaustion, promote Treg and MDSC expansion, skew macrophages toward immunosuppressive M2 phenotypes, and reshape glycolytic and lipid metabolic pathways to generate an immune-refractory microenvironment. In parallel, exosomal circRNAs disseminate long-range immunosuppressive signals, reinforcing therapy resistance and systemic immune dysfunction.
Conversely, a newly recognized subset of "immune-activating circRNAs" induces ferroptosis, immunogenic cell death, and STING-mediated innate immune activation, highlighting the dual nature of circRNA immunoregulation. Recent advances in nanomedicine-spanning lipid nanoparticles, polymeric platforms, and biomimetic membrane-coated carriers-have enabled precise silencing of oncogenic circRNAs and efficient delivery of synthetic therapeutic circRNAs, demonstrating potent synergy with immune checkpoint inhibitors, NK-cell therapy, STING agonists, and ferroptosis inducers.
Although challenges remain, including delivery specificity, biosafety, biomarker standardization, and off-target effects, the convergence of circRNA biology and advanced nanotechnology presents a transformative opportunity to develop next-generation RNA-guided cancer immunotherapies.
Together, these findings position circRNAs as both key mechanistic drivers of immune escape and promising therapeutic targets for nanomedicine-enabled precision immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。